


Integral BioSystems LLC Presented Innovative Formulations at 2016 ARVO Meeting

Integral BioSystems LLC presented posters describing the details of the firm's flagship innovative ophthalmic formulations, NanoM Wafer™ and OcuSurf™.



BEDFORD, MASSACHUSETTS, US,
May 13, 2016 /EINPresswire.com/ --

[Integral BioSystems LLC](#), Boston area CRO specializing in ophthalmological pharmaceutical formulation development, was in the spotlight at the ARVO 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology in Seattle, Washington, as a result of posters presented by the firm describing the company's innovative product offerings. Unique among firms offering fee-for-services pharmaceutical development, Integral BioSystems also offers clients co-development and licensing opportunities utilizing Integral's proprietary, tissue- and cell-targeted sustained release delivery systems.

The focus of the material presented by 23 year industry veteran Dr. Shikha P. Barman, the firm's President, CEO and inventor of the firm's unique drug delivery technologies, was OcuSurf™ and NanoM Wafer™. OcuSurf™ allows highly insoluble drug substances to be administered much more effectively than when formulated as simple suspensions. In the words of the inventor: "This delivery system is transformational and has the potential to replace the frequent and less effective administration of poorly soluble drugs formulated as suspensions, instead offering the drug in a solubilized, tissue permeable, highly bioavailable format."

Integral's other platform innovation is the NanoM delivery system, being developed as a biodegradable, mucoadhesive insert to deliver medications to treat diseases of the anterior chamber, such as uveitis, glaucoma, corneal keratitis, etc. One indication addressed by Integral's NanoM Wafer™ is the treatment of glaucoma by sustained administration of a glaucoma medication. This technology has already gained considerable traction with US and international companies, as well as the NIH, which has awarded a Phase I SBIR Grant to further the product's development. Integral has filed the required IP in support of actively seeking partnerships to co-develop products.

About Integral BioSystems

Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to

achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Dave Karasic
Integral BioSystems, LLC
617-820-8483
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.